MGC26647 Inhibitors
MGC26647 Inhibitors refers to a group of compounds specifically designed to target and modulate the activity of the MGC26647 protein. MGC26647 is a relatively less characterized protein that plays a role in cellular processes. The inhibitors are designed to selectively bind to MGC26647, inhibiting its function or altering its activity in a controlled manner. The rationale behind developing inhibitors for this particular protein is often rooted in the need to understand its biological function and regulatory mechanisms within the cellular context.
The molecular design of MGC26647 Inhibitors involves careful consideration of the protein's structure and its interaction with cellular components. Researchers employ various techniques, such as computational modeling and high-throughput screening, to identify and optimize compounds that exhibit affinity for MGC26647. The goal is to create molecules that can selectively modulate the activity of MGC26647 without affecting other cellular processes adversely. The development of MGC26647 Inhibitors contributes to the broader field of chemical biology, offering tools for researchers to investigate the roles and functions of MGC26647 in different cellular contexts. Understanding the impact of these inhibitors on cellular processes may provide valuable insights into the underlying biology of MGC26647 and its potential relevance in various physiological or pathological conditions.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an EGFR tyrosine kinase inhibitor. MGC26647, if reliant on EGFR signaling for activation, would have reduced activity due to the inhibition of EGFR-mediated pathways, which are critical for the activation of downstream signaling proteins. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that would decrease the activity of MGC26647 if the protein's function is downstream of mTOR signaling, leading to reduced cell growth and proliferation signals. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, which would decrease PI3K/Akt pathway signaling. If MGC26647's activity is PI3K-dependent, this compound would result in reduced activation of the protein. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor, which would decrease ERK pathway signaling. If MGC26647 is activated as part of the MAPK/ERK pathway, inhibition by U0126 would lead to decreased activity of the protein. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a CDK4/6 inhibitor, leading to cell cycle arrest. If MGC26647's function is related to cell cycle progression, inhibition by Palbociclib would decrease its activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, which would decrease p38 MAPK signaling. If MGC26647 operates within this pathway, its activity would be reduced upon inhibition. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor, which would reduce JNK signaling. If MGC26647 is a component of the JNK pathway, its activation would be diminished by SP600125. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor. If the function of MGC26647 depends on proteasome-mediated degradation of regulatory proteins, its activity could be indirectly decreased by Bortezomib. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is a MEK inhibitor that would lead to reduced MEK/ERK signaling. If MGC26647's activation is contingent on the ERK pathway, Trametinib would decrease its activity. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $153.00 $356.00 | 15 | |
ZM-447439 is an Aurora kinase inhibitor. If MGC26647 plays a role in mitosis that is regulated by Aurora kinases, its activity would be diminished by ZM-447439. | ||||||